The staff and facilities of CPU and PRS are shared. Well known and experienced scientists (US and Hungarien) are members of the Scientific Advisory Board of both organisations.
   There is an independent Quality Assurence Officer.

THE BIOEQUIVALENCE STUDIES PERFORMED
IN 1997-2000 BY CPU AND PRS LTD., THOSE BETWEEN 2001-2017 ARE NOT LISTED

	Test and reference drug	Number of Volunteers
1.	Alpha D3 v. Alfa-D3	36
2.	Naproxen v. Naprosyn	24
3.	Pentoxifillyn 600 mg v. Trental 600 mg	24
4.	Enalapril 5 mg v. Innovace 5 mg	24
5.	Enalapril 20 mg v. Innovace 20 mg	26
6.	Famotidine 20 mg v. Pepcidin 20 mg	24
7.	Famotidine 40 mg v. Pepcidin 40 mg	24
8.	Omeprazole 40 mg v. Antra 40 mg	28
9.	Mephaquin v. Lariam	32
10.	Diltiazem v. Dilatam	60
11.	Morphine v. MST Continus	24
12.	Trialkim I. v. Trisequens I.	26
13.	Trialkim II. v. Trisequens II.	26
14.	Verapamil 40 mg v. Isoptin 40 mg	24
15.	Verapamil 80 mg v. Isoptin 80 mg	24
16.	Mephaquin v. Mephaquin formulation v. Lariam	32
17.	Captopril/Hydrochlorothiazide 50/25 mg v. Capozide	30
18.	Captopril/Hydrochlorothiazide 25/25 mg v. Capozide	30
19.	Fluvoxamine v. Floxyfar 100 mg	30
20.	Loratadine v. Claritine	48
21.	Diamox v. Diazomid	26
22.	Gefulvin v. Griseofulvin	28
23.	Clemastine v. Tavegyl	31
24.	Mephaquine v. Lariam	40
25.	Propranolol v. Inderal	28
26.	Simvastatin v. Zocor	36

   The results of these studies were used for submission to registration authorities in Hungary and all over the world.
   Up to now all our report on studies performed by PRS and CPU have always been accepted by any registration authority. This is a 100% score. We consider this an acknowledgement of the quality of our work.